Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir

Niamh Higgins, Barry S. Zingman, Judianne Slish, Richard C. Reichman, Margaret A Fischl, Barbara Gripshover, Kelly Tooley, Naomi Boston, Alan Forrest, Dan Brazeau, Linda M. Catanzaro, Robin DiFrancesco, Francesco Lliguicota, Qing Ma, Gene D. Morse

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Substance use is highly prevalent in HIV-infected individuals in the United States, and clinical management is complicated by the need for antiretroviral treatment, addiction therapy, variable medication adherence, and co-morbidities. The interrelation between HIV and substance use prompted our investigation to examine substance use and self-reported medication adherence in patients receiving the HIV-1 protease inhibitors, atazanavir (ATV) or lopinavir (LPV). ATV and LPV pharmacokinetics were determined by measuring plasma concentrations in subjects with active substance use (SU group) or with no active substance use (NSU group). No difference in adherence was observed between groups (p > 0.05). The mean SU ATV trough was 0.550±0.45 μg/mL; the mean NSU ATV trough was 0.780±0.590 μg/mL (p > 0.05). The mean SU LPV trough was 4.02±2.39 μg/mL; the mean NSU LPV trough was 6.67±0.910 μg/mL (p = 0.01). Co-factors found to be associated with variation in ATV and LPV concentrations included concurrent methadone use, cigarette smoking, and substance use status. These data indicate that chronic HIV treatment may be assisted with plasma concentration monitoring to identify those patients who may require dosage modification and/or regimen adjustment in order to optimize antiretroviral effects.

Original languageEnglish
Pages (from-to)488-494
Number of pages7
JournalAmerican Journal on Addictions
Volume16
Issue number6
DOIs
StatePublished - Nov 1 2007

Fingerprint

Lopinavir
Pharmacokinetics
Medication Adherence
HIV
HIV Protease Inhibitors
Social Adjustment
Methadone
Therapeutics
Smoking
Atazanavir Sulfate
Morbidity

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. / Higgins, Niamh; Zingman, Barry S.; Slish, Judianne; Reichman, Richard C.; Fischl, Margaret A; Gripshover, Barbara; Tooley, Kelly; Boston, Naomi; Forrest, Alan; Brazeau, Dan; Catanzaro, Linda M.; DiFrancesco, Robin; Lliguicota, Francesco; Ma, Qing; Morse, Gene D.

In: American Journal on Addictions, Vol. 16, No. 6, 01.11.2007, p. 488-494.

Research output: Contribution to journalArticle

Higgins, N, Zingman, BS, Slish, J, Reichman, RC, Fischl, MA, Gripshover, B, Tooley, K, Boston, N, Forrest, A, Brazeau, D, Catanzaro, LM, DiFrancesco, R, Lliguicota, F, Ma, Q & Morse, GD 2007, 'Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir', American Journal on Addictions, vol. 16, no. 6, pp. 488-494. https://doi.org/10.1080/10550490701641256
Higgins, Niamh ; Zingman, Barry S. ; Slish, Judianne ; Reichman, Richard C. ; Fischl, Margaret A ; Gripshover, Barbara ; Tooley, Kelly ; Boston, Naomi ; Forrest, Alan ; Brazeau, Dan ; Catanzaro, Linda M. ; DiFrancesco, Robin ; Lliguicota, Francesco ; Ma, Qing ; Morse, Gene D. / Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. In: American Journal on Addictions. 2007 ; Vol. 16, No. 6. pp. 488-494.
@article{4c10dd384b9a42fd97b669947376907a,
title = "Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir",
abstract = "Substance use is highly prevalent in HIV-infected individuals in the United States, and clinical management is complicated by the need for antiretroviral treatment, addiction therapy, variable medication adherence, and co-morbidities. The interrelation between HIV and substance use prompted our investigation to examine substance use and self-reported medication adherence in patients receiving the HIV-1 protease inhibitors, atazanavir (ATV) or lopinavir (LPV). ATV and LPV pharmacokinetics were determined by measuring plasma concentrations in subjects with active substance use (SU group) or with no active substance use (NSU group). No difference in adherence was observed between groups (p > 0.05). The mean SU ATV trough was 0.550±0.45 μg/mL; the mean NSU ATV trough was 0.780±0.590 μg/mL (p > 0.05). The mean SU LPV trough was 4.02±2.39 μg/mL; the mean NSU LPV trough was 6.67±0.910 μg/mL (p = 0.01). Co-factors found to be associated with variation in ATV and LPV concentrations included concurrent methadone use, cigarette smoking, and substance use status. These data indicate that chronic HIV treatment may be assisted with plasma concentration monitoring to identify those patients who may require dosage modification and/or regimen adjustment in order to optimize antiretroviral effects.",
author = "Niamh Higgins and Zingman, {Barry S.} and Judianne Slish and Reichman, {Richard C.} and Fischl, {Margaret A} and Barbara Gripshover and Kelly Tooley and Naomi Boston and Alan Forrest and Dan Brazeau and Catanzaro, {Linda M.} and Robin DiFrancesco and Francesco Lliguicota and Qing Ma and Morse, {Gene D.}",
year = "2007",
month = "11",
day = "1",
doi = "10.1080/10550490701641256",
language = "English",
volume = "16",
pages = "488--494",
journal = "American Journal on Addictions",
issn = "1055-0496",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir

AU - Higgins, Niamh

AU - Zingman, Barry S.

AU - Slish, Judianne

AU - Reichman, Richard C.

AU - Fischl, Margaret A

AU - Gripshover, Barbara

AU - Tooley, Kelly

AU - Boston, Naomi

AU - Forrest, Alan

AU - Brazeau, Dan

AU - Catanzaro, Linda M.

AU - DiFrancesco, Robin

AU - Lliguicota, Francesco

AU - Ma, Qing

AU - Morse, Gene D.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Substance use is highly prevalent in HIV-infected individuals in the United States, and clinical management is complicated by the need for antiretroviral treatment, addiction therapy, variable medication adherence, and co-morbidities. The interrelation between HIV and substance use prompted our investigation to examine substance use and self-reported medication adherence in patients receiving the HIV-1 protease inhibitors, atazanavir (ATV) or lopinavir (LPV). ATV and LPV pharmacokinetics were determined by measuring plasma concentrations in subjects with active substance use (SU group) or with no active substance use (NSU group). No difference in adherence was observed between groups (p > 0.05). The mean SU ATV trough was 0.550±0.45 μg/mL; the mean NSU ATV trough was 0.780±0.590 μg/mL (p > 0.05). The mean SU LPV trough was 4.02±2.39 μg/mL; the mean NSU LPV trough was 6.67±0.910 μg/mL (p = 0.01). Co-factors found to be associated with variation in ATV and LPV concentrations included concurrent methadone use, cigarette smoking, and substance use status. These data indicate that chronic HIV treatment may be assisted with plasma concentration monitoring to identify those patients who may require dosage modification and/or regimen adjustment in order to optimize antiretroviral effects.

AB - Substance use is highly prevalent in HIV-infected individuals in the United States, and clinical management is complicated by the need for antiretroviral treatment, addiction therapy, variable medication adherence, and co-morbidities. The interrelation between HIV and substance use prompted our investigation to examine substance use and self-reported medication adherence in patients receiving the HIV-1 protease inhibitors, atazanavir (ATV) or lopinavir (LPV). ATV and LPV pharmacokinetics were determined by measuring plasma concentrations in subjects with active substance use (SU group) or with no active substance use (NSU group). No difference in adherence was observed between groups (p > 0.05). The mean SU ATV trough was 0.550±0.45 μg/mL; the mean NSU ATV trough was 0.780±0.590 μg/mL (p > 0.05). The mean SU LPV trough was 4.02±2.39 μg/mL; the mean NSU LPV trough was 6.67±0.910 μg/mL (p = 0.01). Co-factors found to be associated with variation in ATV and LPV concentrations included concurrent methadone use, cigarette smoking, and substance use status. These data indicate that chronic HIV treatment may be assisted with plasma concentration monitoring to identify those patients who may require dosage modification and/or regimen adjustment in order to optimize antiretroviral effects.

UR - http://www.scopus.com/inward/record.url?scp=33947601056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947601056&partnerID=8YFLogxK

U2 - 10.1080/10550490701641256

DO - 10.1080/10550490701641256

M3 - Article

C2 - 18058416

AN - SCOPUS:33947601056

VL - 16

SP - 488

EP - 494

JO - American Journal on Addictions

JF - American Journal on Addictions

SN - 1055-0496

IS - 6

ER -